Evaluation of fibrinolysis using microCT in both in vitro and in vivo model

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F20%3AN0000087" target="_blank" >RIV/00027162:_____/20:N0000087 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.bruker.com/events/virtual-mr-tour/pci-microct-virtual-rendezvous-2020.html" target="_blank" >https://www.bruker.com/events/virtual-mr-tour/pci-microct-virtual-rendezvous-2020.html</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluation of fibrinolysis using microCT in both in vitro and in vivo model

Popis výsledku v původním jazyce

Thromboembolic diseases such as acute ischemic stroke or pulmonary embolism are leading causes of mortality and morbidity in humans worldwide. Thrombolysis is a pharmacological treatment using an infusion of tissue plasminogen activator (tPA) (also known as alteplase) which leads to lysis of the blood-clot inside vessel (1). Introduction of novel thrombolytic drugs requires preclinical evaluation of its efficacy before applying to human patients. In order to establish robust and simple preclinical testing method of novel thrombolytic/fibrinolytic drugs, in vitro stroke model under constant flow was prepared to test fibrinolytic effect of alteplase on a contrast agent-labelled fibrin clot inside artificial arteria. Clot size volume after drug exposure was measured using microCT. Furthermore, contrast agent-labelled clots were injected to rats and fibrinolytic efficacy of alteplase was evaluated by measuring clot volume in time using microCT. 3-D rendering volume of clots in the MCA in vitro model showed obvious decreasing trend in a clot’s volume in time (Fig 1.). Recanalization time for fibrin clots using microCT evaluation was 120 min. Clot volume at time 0 significantly differ from those recorded at time 120 min. In vivo experiment showed a significant decrease of clot size in animals treated with rtPA. Both in vitro and in vivo methods presented are robust, easy and reliable tools for preclinical testing of novel thrombolytic drugs. MicroCT provides accurate estimate of clot volume in live animals. Still, further standardization of these methods are needed.

Název v anglickém jazyce

Evaluation of fibrinolysis using microCT in both in vitro and in vivo model

Popis výsledku anglicky

Thromboembolic diseases such as acute ischemic stroke or pulmonary embolism are leading causes of mortality and morbidity in humans worldwide. Thrombolysis is a pharmacological treatment using an infusion of tissue plasminogen activator (tPA) (also known as alteplase) which leads to lysis of the blood-clot inside vessel (1). Introduction of novel thrombolytic drugs requires preclinical evaluation of its efficacy before applying to human patients. In order to establish robust and simple preclinical testing method of novel thrombolytic/fibrinolytic drugs, in vitro stroke model under constant flow was prepared to test fibrinolytic effect of alteplase on a contrast agent-labelled fibrin clot inside artificial arteria. Clot size volume after drug exposure was measured using microCT. Furthermore, contrast agent-labelled clots were injected to rats and fibrinolytic efficacy of alteplase was evaluated by measuring clot volume in time using microCT. 3-D rendering volume of clots in the MCA in vitro model showed obvious decreasing trend in a clot’s volume in time (Fig 1.). Recanalization time for fibrin clots using microCT evaluation was 120 min. Clot volume at time 0 significantly differ from those recorded at time 120 min. In vivo experiment showed a significant decrease of clot size in animals treated with rtPA. Both in vitro and in vivo methods presented are robust, easy and reliable tools for preclinical testing of novel thrombolytic drugs. MicroCT provides accurate estimate of clot volume in live animals. Still, further standardization of these methods are needed.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů